| Budget Amount *help |
¥16,510,000 (Direct Cost: ¥12,700,000、Indirect Cost: ¥3,810,000)
Fiscal Year 2017: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2016: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
|
|---|
| Outline of Final Research Achievements |
IF7 bound to annexin 1 (Anxa1), which the endothelial surface receptor. Because Anxa1 is a highly specific tumor vasculature surface marker, we confirmed that the IF7 peptide could target anticancer drugs to the tumor vasculature. Then, we synthesized highly-pure new anticancer drug IF7-TXL which conjugate paclitaxel (TXL) with IF7 and investigated the antitumor effect using a cancer bearing mouse. In consideration of a future of IF7, we synthesized D-type IF7 and developed the antineoplastic agent of the hybrid peptide type based on new efficacy. We showed excellent antitumor effect in a highly-detailed pharmacological test.
|
